Compare AbbVie Inc (ABBV) vs Invesco Ltd. (IVZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Invesco Ltd. — how do they compare? AbbVie Inc trades at $253.63 (market cap $449.91B), while Invesco Ltd. trades at $27.06 (market cap $12.15B). The key difference: AbbVie Inc is far larger — about 37× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| ABBV | IVZ | |
|---|---|---|
Market Cap | $449.91B | $12.15B |
Sector | Health | Financials |
52-Week High | $261.07 | $29.44 |
52-Week Low | $184.85 | $16.69 |
Enterprise Value | $513.38B | $22.39B |
Dividend Yield | 2.72% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Invesco (IVZ) trades at $27.40, up 1.44% today, with a bullish technical signal from moving averages and support at $27. The company reported mixed Q1 2026 earnings, missing estimates, but has beaten expectations in two prior quarters. Revenue grew to $6.38B in 2025, though net income was negative at -$281.70M. Operating cash flow remains strong at $1.53B, and a dividend of $0.22 is scheduled for June 2026.
Outlook: Analyst consensus is mixed with 43% buy ratings and a $29.44 price target, suggesting modest upside. Risks include persistent negative profitability and competitive pressures in asset management. The stock offers value with a P/E of 19.48 but requires monitoring of earnings turnaround and expense management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
